ARTICLES BY MATTHEW PILLAR
COVID-19 And The Next Chapter In Ansun’s Turnaround Story
How Dr. Nancy Chang turned an embattled company in financial freefall and on the heels of clinical failure into a leading clinical-stage biopharma—and how the disruption of a global pandemic made Ansun Biopharma a formidable contender in the treatment of COVID-19.
The Compounded Risk Of Early-Stage Biopharma Licensing Deals
For emerging biopharma firms, licensing options can equal a boon to the business when cash runways are short and financing options run thin. But, there’s a catch. Most licensed candidates fail. And, according to a new paper, rushed licensing deals on the heels of phase 3 clinical failures only compound the disappointment.
New FDA Guidance For Clinical Trials Disrupted By COVID-19
During this unprecedented time full of unanticipated challenges for biopharmas, FDA has issued new guidance that offers advice on adjusting clinical trial protocols in the midst of the fast-spreading and ill-understood virus SARSCoV-2 and its resulting COVID-19.
Is Biopharma’s Response To Coronavirus Off The Mark?
As biopharmas aplenty race to develop a vaccine, CureLab’s Alex Shneider says an incorrect approach risks turning the currently insignificant coronavirus threat into a deadly pandemic. He suggests that we instead focus on the development of adjuvants and immunostimulants to protect the elderly.
Nurturing A Nascent Colorado Biotech Hub
The Colorado BioScience Association is pioneering a training and education continuum that cultivates talent from middle school to the biotech C-suite.
The Perilous Development Of A Potential Biologic Blockbuster
CytoDyn's leronlimab is under FDA review for Breakthrough Therapy status. Its path from forgotten molecule to near market readiness was riddled with financial and process challenges.
Early-Stage Biopharma Funding Advice From A Leading VC
5AM Ventures Senior Associate Jason Ruth, Ph.D. dished some insider advice to biotech fund seekers in the Pittsburgh LifeX Labs community, and BioProcess Online was there to catch his talk. Here are the highlights.
How The Medical Innovation Act Could Stifle Medical Innovation
The reincarnated bill targeting big pharma is exemplary of congressional inefficiency and over-legislation. Instead, congress should get better at negotiating and appropriating settlements in the existing system.
Outsourcing Insights From A Tech Transfer Veteran
Explore tech transfer expert Anthony Grenier's opinions on the most common mistakes he sees, how to avoid them, and planning ahead to beat the CMO capacity crunch.